In this issue:
Azacitidine + venetoclax in high-risk MDS or CMML
Three consolidation cytarabine doses in intermediate- and adverse-risk AML
Real-world ruxolitinib use for myelofibrosis focusing on RBC transfusion
Prophylactic tranexamic acid in haematological malignancies
Treatment-free remission in CML treated front-line with nilotinib
Real-world healthcare utilisation and costs of CAR T-cells in DLBCL
Sutimlimab improves QOL in cold agglutinin disease
Thrombopoietin receptor agonists: health-related QOL and platelet transfusion in MDS
Postmarketing anagrelide safety and efficacy in essential thrombocythaemia
Obinutuzumab in DLBCL
Please login below to download this issue (PDF)